EP1012180B1 — Hepatitis c inhibitor peptide analogues
Assigned to Boehringer Ingelheim Canada Ltd · Expires 2004-12-01 · 21y expired
What this patent protects
Compound of formula (I) active against the Hepatitis C virus: wherein B is an acyl derivative; a is 0 or 1; R6, when present, is carboxy(lower)alkyl; b is 0 or 1; R5, when present, is C1-6 alkyl, or carboxy (lower)alkyl; Y is H or C1-6 alkyl; R4 is C1-10 alkyl; R3 is C1-10 alkyl;…
USPTO Abstract
Compound of formula (I) active against the Hepatitis C virus: wherein B is an acyl derivative; a is 0 or 1; R6, when present, is carboxy(lower)alkyl; b is 0 or 1; R5, when present, is C1-6 alkyl, or carboxy (lower)alkyl; Y is H or C1-6 alkyl; R4 is C1-10 alkyl; R3 is C1-10 alkyl; W is -NH-CH(R2)-C(O)-, wherein R2 is C1-6 alkyl; C6 or C10 aryl; C7-16 aralkyl; or carboxy (lower)alkyl; or W is a proline derivative; Q is a group of the formula -Z(R1)-C(O)-R13, wherein Z is CH or N; R1 is C1-6 alkyl or C1-6 alkenyl both optionally substituted with thio or halo,; and R13 is an activated carbonyl substituent, or Q is a phosphonate group of the formula -CH(R1)-P(O)R15R16 wherein R15 and R16 are independently C6-20 aryloxy; and R1 is as defined above.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.